Mutant KRAS peptide antigen

The mutant KRAS peptide antigen refers to peptide fragments derived from oncogenic mutations in the KRAS gene (such as G12V, G12D, G12C) that create tumor-specific neoantigens presented on the cell surface by MHC class I molecules (notably HLA-A*11:01 and HLA-C*08:02)[1][2][3][4]. These neoantigenic peptides differ from normal self-peptides by a single amino acid, forming unique tumor-associated epitopes recognized by T cell receptors (TCRs) or engineered immune therapies. Recognition and targeting of the mutant KRAS peptide/MHC complex enables selective immunotherapeutic approaches, including TCR-T, CAR-T, and bispecific antibody therapies directed against cancer cells harboring these KRAS mutations[1][2][3]. The abundance of mutant peptides on tumor cells is usually low, and effective immune targeting requires high-affinity and specificity of the engineered TCR or antibody constructs to avoid off-target toxicity. The approach is mainly relevant for KRAS-driven malignancies and is subject to HLA haplotype constraint for proper peptide-MHC presentation[1][2][3][4].

Other names

KRAS neoantigenKRAS-G12V mutant peptideKRAS G12D neoantigenMutant KRAS peptideKRAS mutant neoantigenKRAS mutant peptide antigen

TCR binding to mutant KRAS peptide-HLA complexes resulting in tumor cell killing[1] Redirected T cell response via bispecific or CAR-T platforms[2][3] Induction of cytotoxicity in peptide-presenting tumor cells